肺癌领域文献更新7月刊EX.pdfVIP

LUNG CANCER PUBLICATION ALERT JULY 2014 肺癌文献更新 ■ 本回复仅为学术交流之目的供中华人民共和国境内医学专业人士参考。 医疗卫生专业人士做出的任何与治疗有关的决定应参考国家食品药品监督管理总局批准的药品说明书 ； 详见 未经授权 ，该资料不得翻印或散发 目录 LUNG CANCER JULY 2014 荟萃分析 Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis. 阿法替尼治疗 EGFR-突变阳性 NSCLC 的网络荟萃分析5 回顾性分析 Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma. 既往EGFR 酪氨酸激酶抑制剂治疗不会影响后续培美曲塞+铂类治疗在未进行化疗的 EGFR-突变肺腺癌患 者中的疗效6 临床研究 Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Ramucirumab 联合多西他赛对比安慰剂联合多西他赛二线治疗含铂剂方案治疗后发生疾病进展的Ⅳ期非 小细胞肺癌患者（REVEL ）：一项多中心、双盲、随机化3 期试验 7 Radiation pneumonitis in patients with non-small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy. 厄洛替尼同步胸部放疗治疗非小细胞肺癌患者中发生的放射性肺炎9 Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and ErlotinibLung Cancer Trial (DELTA). 厄洛替尼对比多西他赛二线或三线治疗晚期非小细胞肺癌患者的随机 III 期试验：多西他赛和厄洛替尼肺癌 试验(DELTA) 10 A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non-Small-Cell Lung Cancer. 多西他赛联合或不联合 PX-866 （一种不可逆转的口服磷脂酰肌醇3-激酶抑制剂）治疗复发或转移性非小 细胞肺癌患者的一项随机、II 期临床试验 11 Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spl